AU769897B2 - Use of cholesterol-lowering agent - Google Patents

Use of cholesterol-lowering agent Download PDF

Info

Publication number
AU769897B2
AU769897B2 AU23051/00A AU2305100A AU769897B2 AU 769897 B2 AU769897 B2 AU 769897B2 AU 23051/00 A AU23051/00 A AU 23051/00A AU 2305100 A AU2305100 A AU 2305100A AU 769897 B2 AU769897 B2 AU 769897B2
Authority
AU
Australia
Prior art keywords
per day
agent
levels
administration
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU23051/00A
Other languages
English (en)
Other versions
AU2305100A (en
Inventor
Ali Raza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU769897(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902590.0A external-priority patent/GB9902590D0/en
Priority claimed from GBGB9921062.7A external-priority patent/GB9921062D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2305100A publication Critical patent/AU2305100A/en
Application granted granted Critical
Publication of AU769897B2 publication Critical patent/AU769897B2/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU23051/00A 1999-02-06 2000-02-01 Use of cholesterol-lowering agent Revoked AU769897B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9902590 1999-02-06
GBGB9902590.0A GB9902590D0 (en) 1999-02-06 1999-02-06 Use of cholesterol-lowering agent
GB9921062 1999-09-08
GBGB9921062.7A GB9921062D0 (en) 1999-09-08 1999-09-08 Use of cholestrol-lowering agent
PCT/GB2000/000285 WO2000045819A1 (en) 1999-02-06 2000-02-01 Use of cholesterol-lowering agent

Publications (2)

Publication Number Publication Date
AU2305100A AU2305100A (en) 2000-08-25
AU769897B2 true AU769897B2 (en) 2004-02-05

Family

ID=26315084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23051/00A Revoked AU769897B2 (en) 1999-02-06 2000-02-01 Use of cholesterol-lowering agent

Country Status (22)

Country Link
EP (1) EP1150679A1 (enExample)
JP (2) JP2002536333A (enExample)
KR (1) KR100699287B1 (enExample)
CN (1) CN1347320A (enExample)
AR (1) AR022462A1 (enExample)
AU (1) AU769897B2 (enExample)
BR (1) BR0007991A (enExample)
CA (1) CA2358641A1 (enExample)
CZ (1) CZ20012631A3 (enExample)
EE (1) EE04659B1 (enExample)
HK (1) HK1040924A1 (enExample)
HU (1) HUP0105019A3 (enExample)
ID (1) ID30131A (enExample)
IL (1) IL144662A0 (enExample)
IS (1) IS5996A (enExample)
MY (1) MY136382A (enExample)
NO (1) NO319827B1 (enExample)
NZ (1) NZ512681A (enExample)
PL (1) PL349137A1 (enExample)
SK (1) SK11112001A3 (enExample)
TR (1) TR200102236T2 (enExample)
WO (1) WO2000045819A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
SE0103509D0 (sv) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
US8436028B2 (en) 2007-06-20 2013-05-07 Merck Sharp & Dohme Corp CETP inhibitors derived from benzoxazole arylamides
US8445480B2 (en) 2007-06-20 2013-05-21 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
EP2166847B1 (en) * 2007-06-20 2014-11-19 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
EP2216095A1 (en) * 2009-01-27 2010-08-11 Koninklijke Philips Electronics N.V. Microfluidic device for full blood count

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles

Also Published As

Publication number Publication date
NO319827B1 (no) 2005-09-19
NZ512681A (en) 2003-12-19
EE04659B1 (et) 2006-08-15
CN1347320A (zh) 2002-05-01
HUP0105019A3 (en) 2003-02-28
IS5996A (is) 2001-07-10
WO2000045819A1 (en) 2000-08-10
KR100699287B1 (ko) 2007-03-26
BR0007991A (pt) 2001-11-06
AR022462A1 (es) 2002-09-04
NO20013810D0 (no) 2001-08-03
NO20013810L (no) 2001-10-03
EE200100404A (et) 2002-10-15
TR200102236T2 (tr) 2001-12-21
KR20010089631A (ko) 2001-10-06
JP2011137023A (ja) 2011-07-14
CA2358641A1 (en) 2000-08-10
AU2305100A (en) 2000-08-25
EP1150679A1 (en) 2001-11-07
IL144662A0 (en) 2002-05-23
SK11112001A3 (sk) 2002-02-05
JP2002536333A (ja) 2002-10-29
PL349137A1 (en) 2002-07-01
MY136382A (en) 2008-09-30
ID30131A (id) 2001-11-08
CZ20012631A3 (cs) 2001-10-17
HK1040924A1 (zh) 2002-06-28
HUP0105019A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
KR100815042B1 (ko) 이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(ｚｄ－４５２２)의 용도
Miller et al. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
Catapano et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients
JP2011137023A (ja) コレステロール低下薬の使用
EP0671171A1 (en) Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events
KR20010101790A (ko) (ｅ)-7-[4-(4-플루오로페닐)-6-이소프로필-2-[메틸(메틸술포닐)아미노]피리미딘-5-일](3ｒ,5ｓ)-3,5-디히드록시헵트-6-엔산 및 ｐ450 이소효소 3ａ4의 억제제, 유도제 또는기질을 함유하는 약물 조합물
AU2016233257B2 (en) Fixed dose combinations comprising ETC1002 and one or more statins for treating or reducing cardiovascular risk
Guay Update on fenofibrate
KR20050110017A (ko) Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
EP1272219B1 (en) New combination of a betablocker and a cholesterol-lowering agent
Insua et al. Fenofibrate or gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study
Whitfield et al. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase
CN110063944B (zh) 一种苯磺酸左旋氨氯地平阿托伐他汀钙片及其制备方法
ZA200401412B (en) Use of atazanavir in HIV therapy.
MXPA01007294A (es) Uso de un agente que reduce colesterol
CN102755322B (zh) 一种乐卡地平和阿托伐他汀复方制剂
Group IV A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia
AU2014230304A1 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CN103169707B (zh) 月桂酸单甘油酯的医药新用途
Ballantyne et al. American
WO2007142581A1 (en) Combination product for the treatment or prevention of dyslipidaemia
HU226062B1 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
HK1051325B (en) New combination of a betablocker and a cholesterol-lowering agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)